CLINICAL TRIALS PROFILE FOR OLARATUMAB
✉ Email this page to a colleague
All Clinical Trials for olaratumab
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00913835 ↗ | A Study of Liposomal Doxorubicin With or Without Olaratumab (IMC-3G3) in Platinum-Refractory or Resistant Advanced Ovarian Cancer | Completed | Eli Lilly and Company | Phase 2 | 2009-06-01 | The purpose of this study is to determine if participants with platinum-refractory or platinum-resistant advanced ovarian cancer have a better outcome when treated with Olaratumab (IMC-3G3) in combination with Liposomal Doxorubicin than when treated with Liposomal Doxorubicin alone. |
| NCT00918203 ↗ | A Study of Paclitaxel/Carboplatin With or Without Olaratumab (IMC-3G3) in Previously Untreated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) | Completed | Eli Lilly and Company | Phase 2 | 2010-01-01 | The purpose of this study is to determine if participants with untreated locally advanced or metastatic non-small cell lung cancer have a better outcome when treated with olaratumab in combination with paclitaxel/carboplatin then when treated with paclitaxel/carboplatin alone. |
| NCT01185964 ↗ | A Study of Olaratumab in Soft Tissue Sarcoma | Completed | Eli Lilly and Company | Phase 1/Phase 2 | 2010-10-01 | The main purpose of this study is to gather information about the use of an investigational drug called olaratumab with a drug for soft tissue sarcoma called doxorubicin. |
| NCT01204710 ↗ | A Study of Olaratumab (IMC-3G3) in Prostate Cancer | Completed | Eli Lilly and Company | Phase 2 | 2010-10-01 | This is a study evaluating the safety and efficacy of the monoclonal antibody olaratumab plus mitoxantrone plus prednisone compared to mitoxantrone plus prednisone in metastatic castration-refractory prostate cancer following disease progression or intolerance on docetaxel-based chemotherapy. |
| NCT02326025 ↗ | A Study of Olaratumab and Doxorubicin in Participants With Advanced Soft Tissue Sarcoma | Completed | Eli Lilly and Company | Phase 1 | 2015-01-22 | The purpose of this study is to assess how the body handles olaratumab when it is given with another drug called doxorubicin. The safety and tolerability of these drugs will be studied. Each participant will complete two 21-day cycles in a fixed order. Participants who complete Cycle 2 may continue to receive olaratumab + doxorubicin for an additional six 21-day cycles and then may receive olaratumab alone until discontinuation criteria are met. Screening is required within 21 days prior to first dose. Part B was added in October, 2015 to assess how the body handles a higher dose of olaratumab when given with doxorubicin. Participants may only enroll in one part. |
| NCT02377752 ↗ | A Study of Olaratumab in Japanese Participants With Advanced Cancer | Completed | Eli Lilly and Company | Phase 1 | 2015-03-23 | This study consists of 2 parts (Part A and Part B). The main purpose of Part A is to evaluate safety and side effects of olaratumab in combination with doxorubicin in Japanese participants with a group of rare cancers (advanced solid tumors, especially advanced soft tissue sarcoma [STS].) The main purpose of Part B is to evaluate how much olaratumab gets into the blood stream of Japanese participants with advanced solid tumors and how long it takes the body to get rid of it. |
| NCT02451943 ↗ | A Study of Doxorubicin Plus Olaratumab (LY3012207) in Participants With Advanced or Metastatic Soft Tissue Sarcoma | Active, not recruiting | Eli Lilly and Company | Phase 3 | 2015-09-14 | The main purpose of this study is to evaluate the efficacy of the combination of doxorubicin plus the study drug known as olaratumab versus doxorubicin plus placebo in participants with advanced or metastatic soft tissue sarcoma. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for olaratumab
Condition Name
Clinical Trial Locations for olaratumab
Trials by Country
Clinical Trial Progress for olaratumab
Clinical Trial Phase
Clinical Trial Sponsors for olaratumab
Sponsor Name
